Nursing home antipsychotic legislation set aside

Share this article:
Nursing home antipsychotic legislation set aside
Nursing home antipsychotic legislation set aside

The U.S. Senate did not approve legislation that would strengthen regulations for antipsychotic use in nursing homes, despite overwhelmingly passing a bill it was attached to on Thursday.

Last week, Sens. Herb Kohl (D-WI), Charles Grassley (R-IA) and Richard Blumenthal (D-CT) proposed a regulation that would have standardized protocols for obtaining informed consent before administering antipsychotics for off-label use. The legislation was proposed as an amendment to an existing Food and Drug Administration reauthorization bill (S. 3187), which was passed by the Senate in a 96-1 vote Thursday.

However, a spokesman for the Special Senate Committee on Aging told McKnight's that the nursing home regulation was not voted on and wasn't included in the manager's amendment.

He added that “the amendment was filed to help bring some needed attention to the widespread problem of the misuse of the antipsychotics among frail elders.” Going forward, he said Kohl and Grassley will “look at other legislative vehicles or stand-alone legislation.”

Senate Majority Leader Harry Reid (D-NV) had urged quick passage of the bill, without many amendments. Senators agreed to consider just 17 of them.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.